Extracellular vesicles (EV) analytics combined with liquid biopsy could lead to earlier diagnosis and stratified treatment that will save lives (e.g. cancer mortality) and lower the healthcare burden cost. However, current methods to purify and quantify EVs take a long time, introduce a bias, are costly and imprecise, thereby hampering progress in EV R&D, while the lack of methods to characterize the whole EV directly in crude samples restricts clinical sensitivity in diagnostics. FOx has established a breakthrough label-free fiber-optic technology in an automated platform for biomolecular sensing. The FOx affinity isolation and simultaneous quantification with a sensor dip probe is a new, selective unbiased, automated, scalable, faster and specific method toto accurately quantify and isolate EV directly from crude samples.
